[1] Thrumurthy SG, Chaudry MA, Thrumurthy SSD, et al.  Oesophageal cancer: risks, prevention, and diagnosis[J]. BMJ, 2019, 366: l4373-.   doi: 10.1136/bmj.l4373
[2] 张可领, 魏怡.  腔内近距离放射治疗食管癌的特点和作用[J]. 国际放射医学核医学杂志, 2003, 27(2): 62-65.   doi: 10.3760/cma.j.issn.1673-4114.2003.02.005
Zhang KL, Wei Y.  The characteristics and effects in the treatment of esophageal cancer with intraluminal brachytherapy[J]. Int J Radiat Med Nucl Med, 2003, 27(2): 62-65.   doi: 10.3760/cma.j.issn.1673-4114.2003.02.005
[3] Tamaki T, Ishikawa H, Takahashi T, et al.  Comparison of efficacy and safety of low-dose-rate vs. high-dose-rate intraluminal brachytherapy boost in patients with superficial esophageal cancer[J]. Brachytherapy, 2012, 11(2): 130-136.   doi: 10.1016/j.brachy.2011.05.008
[4] Tormo Ferrero V, Duque Ugarte R, Berenguer Francés MÁ, et al.  Gynecological brachytherapy for postoperative endometrial cancer: dosimetric analysis (Ir-192 vs Co-60)[J]. Clin Transl Oncol, 2017, 19(11): 1409-1413.   doi: 10.1007/s12094-017-1670-x
[5] Gaspar LE, Nag S, Herskovic A, et al.  American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 1997, 38(1): 127-132.   doi: 10.1016/S0360-3016(97)00231-9
[6]

Mayadev J, Benedict SH, Kamrava M. Handbook of image-guided brachytherapy[M]. Switzerland: Springer, 2017: 273−288.
[7] Buzurovic IM, Hansen JL, Bhagwat MS, et al.  Clinical implementation of a novel applicator in high-dose-rate brachytherapy treatment of esophageal cancer[J]. J Contemp Brachytherapy, 2016, 8(4): 319-325.   doi: 10.5114/jcb.2016.61933
[8] Nicolay NH, Rademacher J, Oelmann-Avendano J, et al.  High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer: experience from a large single-center cohort[J]. Strahlenther Onkol, 2016, 192(7): 458-466.   doi: 10.1007/s00066-016-0979-7
[9] Fuccio L, Mandolesi D, Farioli A, et al.  Brachytherapy for the palliation of dysphagia owing to esophageal cancer: a systematic review and meta-analysis of prospective studies[J]. Radiother Oncol, 2017, 122(3): 332-339.   doi: 10.1016/j.radonc.2016.12.034
[10] Hennequin C, Guillerm S, Wong S, et al.  Endoluminal brachytherapy: bronchus and oesophagus[J]. Cancer Radiother, 2018, 22(4): 367-371.   doi: 10.1016/j.canrad.2017.11.013
[11]

Kang SW, Chung JB, Kim KH, et al. Development of dosimetric verification system for patient-specific quality assurance of high-dose-rate brachytherapy[J/OL]. Front Oncol, 2021, 11: 647222[2020-03-30]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985337. DOI: 10.3389/fonc.2021.647222.
[12] Castilla L, Rovirosa À, Ginès À, et al.  Endoluminal brachytherapy in the treatment of oesophageal cancer. Technique description, case report and review of the literature[J]. Rev Esp Enferm Dig, 2015, 107(7): 449-453.
[13] Manner H, Pech O, Heldmann Y, et al.  Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion[J]. Clin Gastroenterol Hepatol, 2013, 11(6): 630-635.   doi: 10.1016/j.cgh.2012.12.040
[14] Okawa T, Dokiya T, Nishio M, et al.  Multi-institutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan[J]. Int J Radiat Oncol Biol Phys, 1999, 45(3): 623-628.   doi: 10.1016/S0360-3016(99)00253-9
[15]

Wang QF, Li T, Lang JY, et al. A retrospective study of californium-252 neutron brachytherapy combined with EBRT versus 3D-CRT in the treatment of esophageal squamous cell cancer[J/OL]. Radiat Oncol, 2015, 10: 212[2020-03-30]. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-015-0520-7. DOI: 10.1186/s13014-015-0520-7.
[16]

Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer[J/OL]. Nat Rev Dis Primers, 2017, 3: 17048[2020-03-30]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168059. DOI: 10.1038/nrdp.2017.48.
[17] Muijs CT, Beukema JC, Mul VE, et al.  External beam radiotherapy combined with intraluminal brachytherapy in esophageal carcinoma[J]. Radiother Oncol, 2012, 102(2): 303-308.   doi: 10.1016/j.radonc.2011.07.021
[18] Kumar S, Dimri K, Khurana R, et al.  A randomised trial of radiotherapy compared with cisplatin chemo-radiotherapy in patients with unresectable squamous cell cancer of the esophagus[J]. Radiother Oncol, 2007, 83(2): 139-147.   doi: 10.1016/j.radonc.2007.03.013
[19] Gaspar LE, Winter K, Kocha WI, et al.  A phaseⅠ/Ⅱstudy of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report[J]. Cancer, 2000, 88(5): 988-995.   doi: 10.1002/(SICI)1097-0142(20000301)88:53.0.CO;2-U
[20]

Montemaggi P, Trombetta M, Brady L. Brachytherapy: an international perspective[M]. Switzerland: Springer, 2016: 231−238.
[21] Cooper JS, Guo MD, Herskovic A, et al.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01)[J]. JAMA, 1999, 281(17): 1623-1627.   doi: 10.1001/jama.281.17.1623
[22] Markar S, Gronnier C, Duhamel A, et al.  Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option?[J]. J Clin Oncol, 2015, 33(33): 3866-3873.   doi: 10.1200/JCO.2014.59.9092
[23] Sudo K, Xiao LC, Wadhwa R, et al.  Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer[J]. J Clin Oncol, 2015, 32(30): 3400-3405.   doi: 10.1200/JCO.2014.56.7156
[24]

Bao Y, Liu SL, Zhou QC, et al. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern[J/OL]. Radiat Oncol, 2013, 8: 241[2020-03-30]. https://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-8-241. DOI: 10.1186/1748-717X-8-241.
[25] Hamai Y, Hihara J, Emi M, et al.  Treatment outcomes and prognostic factors after recurrence of esophageal squamous cell carcinoma[J]. World J Surg, 2018, 42(7): 2190-2198.   doi: 10.1007/s00268-017-4430-8
[26] Muro K, Lordick F, Tsushima T, et al.  Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS[J]. Ann Oncol, 2019, 30(1): 34-43.   doi: 10.1093/annonc/mdy498
[27] Ajani JA, D'Amico TA, Bentrem DJ, et al.  Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2019, 17(7): 855-883.   doi: 10.6004/jnccn.2019.0033
[28] Sinha S, Varagunam M, Park MH, et al.  Brachytherapy in the palliation of oesophageal cancer: effective but impractical?[J]. Clin Oncol (R Coll Radiol), 2019, 31(7): e87-e93.   doi: 10.1016/j.clon.2019.03.045
[29] Fuccio L, Guido A, Hassan C, et al.  Underuse of brachytherapy for the treatment of dysphagia owing to esophageal cancer. An Italian survey[J]. Dig Liver Dis, 2016, 48(10): 1233-1236.   doi: 10.1016/j.dld.2016.07.003
[30] Amdal CD, Jacobsen AB, Sandstad B, et al.  Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase Ⅲ trial[J]. Radiother Oncol, 2013, 107(3): 428-433.   doi: 10.1016/j.radonc.2013.04.008
[31] Rupinski M, Zagorowicz E, Regula J, et al.  Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (RevisedⅡ)[J]. Am J Gastroenterol, 2011, 106(9): 1612-1620.   doi: 10.1038/ajg.2011.178
[32] Lancellotta V, Cellini F, Fionda B, et al.  The role of palliative interventional radiotherapy (brachytherapy) in esophageal cancer: an AIRO (Italian Association of Radiotherapy and Clinical Oncology) systematic review focused on dysphagia-free survival[J]. Brachytherapy, 2020, 19(1): 104-110.   doi: 10.1016/j.brachy.2019.09.005
[33] Frobe A, Jones G, Jaksić B, et al.  Intraluminal brachytherapy in the management of squamous carcinoma of the esophagus[J]. Dis Esophagus, 2009, 22(6): 513-518.   doi: 10.1111/j.1442-2050.2009.00958.x
[34] Kishi K, Iida T, Ojima T, et al.  Esophageal gel-shifting technique facilitating eradicative boost or reirradiation to upper mediastinal targets of recurrent nerve lymph node without damaging esophagus[J]. J Radiat Res, 2013, 54(4): 748-754.   doi: 10.1093/jrr/rrs137
[35]

He M, Cheng G, Zhao H, et al. Interstitial brachytherapy for the isolated lymph node metastasis from different solid cancers[J/OL]. Radiother Oncol, 2016, 119(Suppl 1): S938-939[2020-03-30]. https://www.thegreenjournal.com/article/S0167-8140(16)33235-2/fulltext. DOI: 10.1016/S0167-8140(16)33235-2.
[36] Sun XJ, Han SY, Gu FY, et al.  A retrospective comparison of taxane and fluorouracil-based chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma[J]. J Cancer, 2016, 7(9): 1066-1073.   doi: 10.7150/jca.13547